Fresh2 Group Ltd (FRES)vsWaters Corporation (WAT)
FRES
Fresh2 Group Ltd
$0.85
0.00%
HEALTHCARE · Cap: $2.97M
WAT
Waters Corporation
$302.32
+0.13%
HEALTHCARE · Cap: $29.66B
Smart Verdict
WallStSmart Research — data-driven comparison
Waters Corporation generates 18541% more annual revenue ($3.17B vs $16.98M). WAT leads profitability with a 20.3% profit margin vs 0.0%. WAT earns a higher WallStSmart Score of 60/100 (C).
FRES
Avoid33
out of 100
Grade: F
WAT
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for FRES.
Margin of Safety
-349.9%
Fair Value
$73.17
Current Price
$302.32
$229.15 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 33.8%
Safe zone — low bankruptcy risk
Every $100 of equity generates 29 in profit
Keeps 20 of every $100 in revenue as profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -2.2% — below average capital efficiency
Moderate valuation
Earnings declined 3.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : FRES
The strongest argument for FRES centers on Price/Book.
Bull Case : WAT
The strongest argument for WAT centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 20.3% and operating margin at 33.8%. PEG of 1.25 suggests the stock is reasonably priced for its growth.
Bear Case : FRES
The primary concerns for FRES are EPS Growth, Market Cap, Profit Margin.
Bear Case : WAT
The primary concerns for WAT are P/E Ratio, EPS Growth.
Key Dynamics to Monitor
FRES profiles as a value stock while WAT is a mature play — different risk/reward profiles.
FRES carries more volatility with a beta of 1.28 — expect wider price swings.
WAT is growing revenue faster at 6.8% — sustainability is the question.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
WAT scores higher overall (60/100 vs 33/100), backed by strong 20.3% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fresh2 Group Ltd
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. The company is headquartered in New York, New York.
Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?